• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

出现对泰利霉素和氟喹诺酮类高度耐药的肺炎链球菌临床分离株。

Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones.

作者信息

Faccone Diego, Andres Patricia, Galas Marcelo, Tokumoto Marta, Rosato Adriana, Corso Alejandra

机构信息

Servicio Antimicrobianos, INEI-ANLIS "Dr. Carlos G. Malbrán," Av. Velez Sarsfield 563 (1281), Buenos Aires, Argentina.

出版信息

J Clin Microbiol. 2005 Nov;43(11):5800-3. doi: 10.1128/JCM.43.11.5800-5803.2005.

DOI:10.1128/JCM.43.11.5800-5803.2005
PMID:16272525
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1287838/
Abstract

Streptococcus pneumoniae is a major pathogen causing community-acquired pneumonia and acute bronchitis. Macrolides, fluoroquinolones (FQs), and, recently, telithromycin (TEL) constitute primary therapeutic options, and rare cases of resistance have been reported. In this report, we describe the emergence of an S. pneumoniae clinical isolate with high-level TEL resistance (MIC, 256 microg/ml) and simultaneous resistance to FQs. Ongoing studies are oriented to elucidate the precise mechanism of resistance to TEL.

摘要

肺炎链球菌是引起社区获得性肺炎和急性支气管炎的主要病原体。大环内酯类、氟喹诺酮类（FQs）以及最近的泰利霉素（TEL）是主要的治疗选择，且已有耐药罕见病例的报道。在本报告中，我们描述了一株对泰利霉素具有高水平耐药性（MIC，256μg/ml）且同时对氟喹诺酮类耐药的肺炎链球菌临床分离株的出现。正在进行的研究旨在阐明对泰利霉素耐药的确切机制。

相似文献

1
Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones.出现对泰利霉素和氟喹诺酮类高度耐药的肺炎链球菌临床分离株。
J Clin Microbiol. 2005 Nov;43(11):5800-3. doi: 10.1128/JCM.43.11.5800-5803.2005.
2
Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.在中性粒细胞减少小鼠大腿模型中，泰利霉素对大环内酯类和氟喹诺酮耐药肺炎链球菌的药效学特征。
Antimicrob Agents Chemother. 2005 Jan;49(1):188-94. doi: 10.1128/AAC.49.1.188-194.2005.
3
Mutational analysis of reduced telithromycin susceptibility of Streptococcus pneumoniae isolated clinically in Japan.日本临床分离肺炎链球菌中降低的替考拉宁敏感性的突变分析。
FEMS Microbiol Lett. 2010 Jun;307(1):87-93. doi: 10.1111/j.1574-6968.2010.01962.x. Epub 2010 Mar 19.
4
Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.塞维利亚侵袭性临床分离肺炎链球菌中氟喹诺酮耐药的分子流行病学研究。
Enferm Infecc Microbiol Clin. 2012 Apr;30(4):180-3. doi: 10.1016/j.eimc.2011.10.006. Epub 2012 Feb 24.
5
[Molecular analytical evaluation of macrolide- and ketolide-resistant Streptococcus pneumoniae--mechanism of action of telithromycin and resistance to it].[对大环内酯类和酮内酯类耐药肺炎链球菌的分子分析评估——泰利霉素的作用机制及其耐药性]
Jpn J Antibiot. 2004 Oct;57(5):425-37.
6
High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.肺炎链球菌临床分离株中的高水平替利霉素耐药性。
Antimicrob Agents Chemother. 2007 Mar;51(3):1092-5. doi: 10.1128/AAC.01153-06. Epub 2007 Jan 8.
7
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.16元环大环内酯类药物及泰利霉素对不同基因型的红霉素敏感及耐药化脓性链球菌和肺炎链球菌的活性。
J Antimicrob Chemother. 2007 Jun;59(6):1171-6. doi: 10.1093/jac/dkm089. Epub 2007 Apr 3.
8
Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.德国首例耐泰利霉素肺炎链球菌分离株的分子特征分析
Antimicrob Agents Chemother. 2005 Aug;49(8):3520-2. doi: 10.1128/AAC.49.8.3520-3522.2005.
9
Activity of telithromycin against erythromycin-susceptible and -resistant Streptococcus pneumoniae isolates from adults with invasive infections.泰利霉素对侵袭性感染成年患者中对红霉素敏感及耐药的肺炎链球菌分离株的活性。
Int J Antimicrob Agents. 2004 Dec;24(6):616-8. doi: 10.1016/j.ijantimicag.2004.06.018.
10
Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).意大利耐氟喹诺酮肺炎链球菌菌株的出现与流行病学：哨兵抗菌监测计划（2001 - 2004年）报告
Diagn Microbiol Infect Dis. 2006 Mar;54(3):157-64. doi: 10.1016/j.diagmicrobio.2005.08.012. Epub 2006 Jan 19.

引用本文的文献

1
The macrolide antibiotic renaissance.大环内酯类抗生素的复兴
Br J Pharmacol. 2017 Sep;174(18):2967-2983. doi: 10.1111/bph.13936. Epub 2017 Aug 10.
2
Resistance to Macrolide Antibiotics in Public Health Pathogens.公共卫生病原体对大环内酯类抗生素的耐药性
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):a025395. doi: 10.1101/cshperspect.a025395.
3
Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.结合疫苗时代前后美国耐抗生素肺炎链球菌的生物学和流行病学特征
Clin Microbiol Rev. 2016 Jul;29(3):525-52. doi: 10.1128/CMR.00058-15.
4
A novel ketolide, RBx 14255, with activity against multidrug-resistant Streptococcus pneumoniae.一种新型酮内酯类药物RBx 14255，对多重耐药肺炎链球菌具有活性。
Antimicrob Agents Chemother. 2014 Aug;58(8):4283-9. doi: 10.1128/AAC.01589-13. Epub 2014 Feb 18.
5
Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation.肺炎链球菌对泰利霉素的耐药性是由erm(B)前导序列中的缺失导致的，该缺失增加了rRNA甲基化。
Antimicrob Agents Chemother. 2008 Feb;52(2):435-40. doi: 10.1128/AAC.01074-07. Epub 2007 Dec 3.
6
High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.肺炎链球菌临床分离株中的高水平替利霉素耐药性。
Antimicrob Agents Chemother. 2007 Mar;51(3):1092-5. doi: 10.1128/AAC.01153-06. Epub 2007 Jan 8.
7
Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.来自欧洲的对泰利霉素不敏感的肺炎链球菌临床分离株。
Antimicrob Agents Chemother. 2006 Nov;50(11):3897-900. doi: 10.1128/AAC.00057-06.
8
Streptococcus pneumoniae isolates resistant to telithromycin.对泰利霉素耐药的肺炎链球菌分离株。
Antimicrob Agents Chemother. 2006 May;50(5):1855-8. doi: 10.1128/AAC.50.5.1855-1858.2006.

本文引用的文献

1
Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.2002 - 2003年肺炎链球菌、流感嗜血杆菌、卡他莫拉菌及A组β溶血性链球菌的耐药性。多国GRASP监测项目的结果。
Int J Antimicrob Agents. 2005 Feb;25(2):148-56. doi: 10.1016/j.ijantimicag.2004.09.016.
2
Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study.二氧化碳对替利霉素针对肺炎链球菌的最低抑菌浓度的影响：一项体外-体内研究
Antimicrob Agents Chemother. 2005 Jan;49(1):464-6. doi: 10.1128/AAC.49.1.464-466.2005.
3
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.在患有轻至中度社区获得性肺炎的患者中，与每日两次服用10天克拉霉素的方案相比，每日一次服用5天和7天泰利霉素方案的临床、细菌学疗效及安全性。
J Antimicrob Chemother. 2004 Aug;54(2):515-23. doi: 10.1093/jac/dkh356. Epub 2004 Jul 21.
4
Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.泰利霉素对社区获得性呼吸道感染相关关键病原体的活性。
J Infect. 2004 Aug;49(2):115-25. doi: 10.1016/j.jinf.2004.03.009.
5
Clinical efficacy of ketolides in the treatment of respiratory tract infections.酮内酯类药物治疗呼吸道感染的临床疗效
J Antimicrob Chemother. 2004 Jun;53(6):918-27. doi: 10.1093/jac/dkh169. Epub 2004 Apr 29.
6
Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.泰利霉素对1999年至2003年间收集的13874株肺炎链球菌的活性。
Antimicrob Agents Chemother. 2004 May;48(5):1882-4. doi: 10.1128/AAC.48.5.1882-1884.2004.
7
Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.泰利霉素对大环内酯类耐药和敏感的肺炎链球菌、卡他莫拉菌及流感嗜血杆菌的体外活性比较
J Antimicrob Chemother. 2004 May;53(5):793-6. doi: 10.1093/jac/dkh178. Epub 2004 Mar 31.
8
Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.全球耐氟喹诺酮肺炎链球菌的发病率、分子流行病学及相关突变：来自全球PROTEKT监测项目的数据
J Antimicrob Chemother. 2003 Dec;52(6):944-52. doi: 10.1093/jac/dkg465. Epub 2003 Oct 29.
9
Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.肺炎球菌肺炎中氟喹诺酮类和大环内酯类治疗失败及多重耐药菌株的选择
Emerg Infect Dis. 2003 Sep;9(9):1159-62. doi: 10.3201/eid0909.020810.
10
High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.肺炎链球菌实验室诱导突变体中的高水平替利霉素耐药性。
J Antimicrob Chemother. 2003 Sep;52(3):345-53. doi: 10.1093/jac/dkg348. Epub 2003 Aug 13.